NASDAQ:PRTC - PureTech Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $71.00
  • Forecasted Upside: 86.11 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$38.15
+0.30 (1.20%)

This chart shows the closing price for PRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PureTech Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTC

Analyst Price Target is $71.00
▲ +86.11% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for PureTech Health in the last 3 months. The average price target is $71.00, with a high forecast of $72.00 and a low forecast of $70.00. The average price target represents a 86.11% upside from the last price of $38.15.

This chart shows the closing price for PRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in PureTech Health.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/7/2022SVB LeerinkLower Price TargetOutperform$76.00 ➝ $70.00Low
8/25/2021SVB LeerinkBoost Price TargetOutperform$74.00 ➝ $76.00Medium
8/25/2021Piper SandlerLower Price TargetOverweight$76.00 ➝ $72.00Medium
2/10/2021Piper SandlerBoost Price Target$66.00 ➝ $76.00N/A
1/15/2021SVB LeerinkInitiated CoverageOutperform$70.00N/A
11/17/2020Piper SandlerInitiated CoverageOverweightHigh
(Data available from 1/19/2017 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/20/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
PureTech Health logo
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $38.15
Low: $38.15
High: $38.15

50 Day Range

MA: $39.97
Low: $35.00
High: $46.99

52 Week Range

Now: $38.15
Low: $35.00
High: $65.90

Volume

226 shs

Average Volume

2,838 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of PureTech Health?

The following Wall Street sell-side analysts have issued reports on PureTech Health in the last year: Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for PRTC.

What is the current price target for PureTech Health?

2 Wall Street analysts have set twelve-month price targets for PureTech Health in the last year. Their average twelve-month price target is $71.00, suggesting a possible upside of 86.1%. Piper Sandler has the highest price target set, predicting PRTC will reach $72.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $70.00 for PureTech Health in the next year.
View the latest price targets for PRTC.

What is the current consensus analyst rating for PureTech Health?

PureTech Health currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTC will outperform the market and that investors should add to their positions of PureTech Health.
View the latest ratings for PRTC.

How do I contact PureTech Health's investor relations team?

PureTech Health's physical mailing address is 6 TIDE STREET SUITE 400, BOSTON MA, 02210. The company's listed phone number is 617-482-2333 and its investor relations email address is [email protected] The official website for PureTech Health is www.puretechhealth.com.